ArticleSaudi medical journal2025
Cervical cancer risk and high-risk HPV types distribution in Saudi Arabia: Trends from a national laboratory-based study.
Article in Saudi medical journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Epidemiology of Human Papillomavirus in the Middle East and North Africa: A Review of Genotypic Prevalence, Vaccination Challenges, and Non-Cervical Clinical Outcomes.Diseases (Basel, Switzerland) · 2026Review
- Knowledge and awareness regarding human papillomavirus and its association with oropharyngeal cancer among the general population in Makkah, Saudi Arabia: a cross-sectional study.Frontiers in oncology · 2026Article
- Epidemiology of Human Papillomavirus in Saudi Arabia: A Scoping Review of Prevalence, Genotypes, and Risk Factors.Journal of epidemiology and global health · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTo examine the distribution of human papillomavirus (HPV) genotypes, regional trends, and cytological abnormalities in Saudi Arabia. The findings aim to inform effective cervical cancer prevention strategies. High-risk HPV infections is the leading cause of cervical cancer.
methodsA retrospective, national laboratory-based study was conducted between 2016 and 2024, analyzing 9,096 medical records. Of these patients, 6,005 underwent co-testing of HPV DNA and cytology-based screening, and 3,091 underwent only cytology-based screening. The HPV genotype distribution, temporal trends, and geographic variations were evaluated.
resultsThe HPV positivity rate was 13.84%, with HPV-16 accounting for 25.11% and HPV-18 for 7.55% of cases, while 67.34% of the infections were due to other high-risk strains. The HPV positivity peaked in the 30-39 age group (44.9%) and increased from 5.62% in 2016 to 13.33% in 2024. Jeddah (33.7%) and Riyadh (32.25%) had the highest HPV positivity rates. Among the evaluated cytology samples, 13.41% had precancerous lesions, and 0.64% had cancerous lesions. Notably, 19.37% of HPV-positive cases had normal cytological profiles, reinforcing the importance of co-testing HPV DNA and cytology tests.
conclusionThis study reveals significant age and regional disparities in HPV prevalence in Saudi Arabia, with a predominance of non-16/18 genotypes. Broad vaccine coverage, genotype surveillance, and regionally adapted screening strategies are essential to reduce cervical cancer burden.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.